Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 25, 2023, titled "Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)".
Press Release Oct 25 2023
Filed with NSE · · 3 pages · English
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Oct 20 2023
- Press Release Oct 16 2023
- Press Release Oct 06 2023
- Press Release Sep 29 2023
- Press Release Sep 20 2023
Later from Zydus Lifesciences
- Press Release Oct 30 2023
- Press Release Oct 31 2023
- Press Release Nov 02 2023
- Press Release Nov 03 2023
- Zydus Lifesciences Limited Press Release Nov 06 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences